Jill Bargonetti
Overview
Explore the profile of Jill Bargonetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1950
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu J, Shen Y, Liu J, Xu D, Chang C, Wang J, et al.
Nat Commun
. 2025 Feb;
16(1):1762.
PMID: 39971971
The tumor-suppressive function of p53 is frequently disrupted by mutations in cancers. Missense mutant p53 (mutp53) protein often stabilizes and accumulates to high levels in cancers to promote tumorigenesis through...
2.
Lee R, Ellison V, Forbes D, Gao C, Katanov D, Kern A, et al.
Cancers (Basel)
. 2025 Jan;
16(24.
PMID: 39766093
Background: The metastasis-promoting G-protein-coupled receptor CXC Receptor 4 (CXCR4) is activated by the chemokine CXCL12, also known as stromal cell-derived factor 1 (SDF-1). The CXCL12/CXCR4 pathway in cancer promotes metastasis...
3.
Ellison V, Polotskaia A, Xiao G, Leybengrub P, Qiu W, Lee R, et al.
bioRxiv
. 2024 Feb;
PMID: 38328189
The influence of the metastasis promoting proteins mutant p53 (mtp53) and MDM2 on (CPR) to promote cancer cell survival is understudied. Interactions between the DNA repair choice protein 53BP1 and...
4.
Madorsky Rowdo F, Xiao G, Khramtsova G, Nguyen J, Martini R, Stonaker B, et al.
Cancer Lett
. 2024 Jan;
584:216608.
PMID: 38199587
Poly (ADP-ribose) polymerase inhibitors (PARPi) are used for patients with BRCA1/2 mutations, but patients with other mutations may benefit from PARPi treatment. Another mutation that is present in more cancers...
5.
Wang J, Chang C, Yang X, Zhou F, Liu J, Bargonetti J, et al.
Nat Commun
. 2024 Jan;
15(1):137.
PMID: 38167344
Radiation-induced gastrointestinal syndrome is a major complication and limiting factor for radiotherapy. Tumor suppressor p53 has a protective role in radiation-induced gastrointestinal toxicity. However, its underlying mechanism remains unclear. Here...
6.
Madorsky Rowdo F, Xiao G, Khramtsova G, Nguyen J, Olopade O, Martini R, et al.
bioRxiv
. 2023 Dec;
PMID: 38076873
Poly (ADP-ribose) polymerase inhibitors (PARPi) are used for patients with mutations, but patients with other mutations may benefit from PARPi treatment. Another mutation that is present in more cancers than...
7.
Canar J, Manandhar-Sasaki P, Bargonetti J
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230851
The gene is mutated in over 50% of human cancers, and the gene encodes the ortholog CEP-1. CEP-1 is activated by ultraviolet type C (UVC)-induced DNA damage and activates genes...
8.
Lundine D, Annor G, Chavez V, Maimos S, Syed Z, Jiang S, et al.
Mol Cancer Res
. 2022 Sep;
20(12):1799-1810.
PMID: 36074101
Implications: The C-terminal region of mtp53 confers GOF activity that mediates mtp53-PARP1 and PAR interactions assisting DNA replication, thus implicating new biomarkers for PARP inhibitor therapy.
9.
Lama R, Xu C, Galster S, Querol-Garcia J, Portwood S, Mavis C, et al.
Front Oncol
. 2022 Aug;
12:933446.
PMID: 35992795
MDM2 and MDM4 proteins are key negative regulators of tumor suppressor p53. MDM2 and MDM4 interact their RING domains and form a heterodimer polyubiquitin E3 ligase essential for p53 degradation....
10.
Annor G, Elshabassy N, Lundine D, Conde D, Xiao G, Ellison V, et al.
Front Cell Dev Biol
. 2021 Dec;
9:772315.
PMID: 34881245
The gene is often mutated in cancer, with missense mutations found in the central DNA binding domain, and less often in the C-terminal oligomerization domain (OD). These types of mutations...